ReviewEuropean respiratory review : an official journal of the European Respiratory Society2015
Clinically relevant subgroups in COPD and asthma.
Review in European respiratory review : an official journal of the European Respiratory Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap.Drug design, development and therapy · 2018Pooled it
- CT densitometry in emphysema: a systematic review of its clinical utility.International journal of chronic obstructive pulmonary disease · 2018Pooled it
- The effect of domiciliary noninvasive ventilation on clinical outcomes in stable and recently hospitalized patients with COPD: a systematic review and meta-analysis.International journal of chronic obstructive pulmonary disease · 2016Pooled it
- Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT.Health technology assessment (Winchester, England) · 2025Trial
- Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.Respiratory research · 2019Trial
- Real-Life Effectiveness of Aclidinium/Formoterol on COPD Control: The REDACT Observational Study.International journal of chronic obstructive pulmonary disease · 2026Observational
- Identifying KL-6-Associated Immune Cell Signatures and Key Genes in Emphysematous COPD.Journal of inflammation research · 2025Article
- Role of Complement Components in Asthma: A Systematic Review.Journal of clinical medicine · 2024Review
- Endothelin-1 induces connective tissue growth factor expression in human lung fibroblasts by disrupting HDAC2/Sin3A/MeCP2 corepressor complex.Journal of biomedical science · 2023Article
- Review
- Paucigranulocytic Asthma: Potential Pathogenetic Mechanisms, Clinical Features and Therapeutic Management.Journal of personalized medicine · 2022Review
- Chronic Obstructive Pulmonary Disease: The Present and Future.Biomedicines · 2022Article
- Review
- Eosinophil-derived IL-13 promotes emphysema.The European respiratory journal · 2019Article
- TIPE2 is negatively correlated with tissue factor and thrombospondin-1 expression in patients with bronchial asthma.Experimental and therapeutic medicine · 2018Article
- Increased urinary l-histidine in patients with asthma-COPD overlap: a pilot study.International journal of chronic obstructive pulmonary disease · 2018Article
- Bronchodilator responsiveness or reversibility in asthma and COPD - a need for clarity.International journal of chronic obstructive pulmonary disease · 2018Article
- Noninvasive ventilation with helium-oxygen mixture in hypercapnic COPD exacerbation: aggregate meta-analysis of randomized controlled trials.Annals of intensive care · 2017Review
- Association of chronic obstructive pulmonary disease and hemorrhoids: A nationwide cohort study.Medicine · 2017Observational
- Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation.Biomarker insights · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As knowledge of airways disease has grown, it has become apparent that neither chronic obstructive pulmonary disease (COPD) nor asthma is a simple, easily defined disease. In the past, treatment options for both diseases were limited; thus, there was less need to define subgroups. As treatment options have grown, so has our need to predict who will respond to new drugs. To date, identifying subgroups has been largely reported by detailed clinical characterisation or differences in pathobiology. These subgroups are commonly called "phenotypes"; however, the problem of defining what constitutes a phenotype, whether this should include comorbid diseases and how to handle changes over time has led to the term being used loosely. In this review, we describe subgroups of COPD and asthma patients whose clinical characteristics we believe have therapeutic or major prognostic implications specific to the lung, and whether these subgroups are constant over time. Finally, we will discuss whether the subgroups we describe are common to both asthma and COPD, and give some examples of how treatment might be tailored in patients where the subgroup is clear, but the label of asthma or COPD is not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.